Frequency of mitogen-activated protein kinase and phosphoinositide 3-kinase signaling pathway pathogenic alterations in EUS-FNA sampled malignant lymph nodes in rectal cancer with theranostic potential

Abstract

Targeted next-generation sequencing has the potential to stratify a tumor by molecular subtype and aid the development of a biomarker profile for prognostic risk stratification and theranostic potential. To assess the frequency and distribution of pathogenic alterations in malignant lymph node cytology specimens. Multigene molecular profiling of archived malignant EUS-FNA lymph node cytology specimens using the Ion Ampliseq Cancer Hotspot Panel v2, which targets at least 2855 possible mutations within 50 cancer-associated genes. Single tertiary referral center. Sporadic, treatment naive, locally advanced primary rectal cancer by EUS-FNA (n= 76) who subsequently completed neoadjuvant therapy with on-site oncologic surgery. The frequency and distribution of pathogenic alterations in malignant lymph node cytology specimens by the mitogen-activated protein kinase (MAPK) or phosphoinositide 3-kinase (PI3K) signaling pathways, by KRAS or NRAS wild-type lymph node status, by extramesenteric lymph node status, and by a complete pathologic response status. Eleven patients (14.5%) were 50-gene panel wild-type. Sixty-five patients had 139 pathogenic alterations (2 [1-3] per patient) in 13 of 50 evaluated genes. The following represent a spectrum of identified alterations: TP53 (n= 52; 68.4%), APC (n= 36; 47.4%), KRAS (n= 22; 28.9%), FBXW7 (n= 8; 10.5%), NRAS (n= 6; 7.9%), PIK3CA (n= 4; 5.3%), SMAD4 (n= 3; 3.9%), and BRAF (n= 3; 3.9%). Pathogenic alterations were identified in the MAPK and PI3K signaling pathways in 41% and 5% of patients, respectively. Findings were limited to a 50 cancer-associated gene analysis. Molecular EUS lymph node assessments using cancer "hotspot" panels can identify pathogenic alteration frequency and distribution and have theranostic potential for individualized patient care.